| scholarly article | Q13442814 |
| P2093 | author name string | Tak PP | |
| Haringman JJ | |||
| Kraan MC | |||
| Smeets TJ | |||
| Zwinderman KH | |||
| P2860 | cites work | Methotrexate and radiographic disease progression in patients with rheumatoid arthritis | Q78108507 |
| The development of clinical signs of rheumatoid synovial inflammation is associated with increased synthesis of the chemokine CXCL8 (interleukin-8) | Q24792930 | ||
| The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 | ||
| Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor | Q28297700 | ||
| Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm | Q29547181 | ||
| Chemokines: a new classification system and their role in immunity | Q29615663 | ||
| Chemokines--chemotactic cytokines that mediate inflammation | Q29616433 | ||
| Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? | Q33937489 | ||
| Clinical outcome measures in rheumatoid arthritis | Q34071257 | ||
| Macrophage inflammatory protein-1 alpha. A novel chemotactic cytokine for macrophages in rheumatoid arthritis | Q34129985 | ||
| Chemokines in pathology and medicine | Q34328278 | ||
| Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model | Q37383845 | ||
| Quantification of the cell infiltrate in synovial tissue by digital image analysis | Q39528308 | ||
| Microscopic measurement of cellular infiltration in the rheumatoid arthritis synovial membrane: a comparison of semiquantitative and quantitative analysis | Q40838835 | ||
| "The good, the bad, and the ugly." The role of chemokines in models of human disease. | Q40982121 | ||
| Chemokine receptors: gateways to inflammation and infection | Q41193992 | ||
| Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis | Q43607170 | ||
| Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group | Q43760451 | ||
| American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis | Q47643186 | ||
| Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. | Q50850177 | ||
| Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice | Q57019206 | ||
| CD8+ and CD45RA+ human peripheral blood lymphocytes are potent sources of macrophage inflammatory protein 1α, interleukin-8 and RANTES | Q59200610 | ||
| The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis | Q68109843 | ||
| Chemokine expression in rheumatoid arthritis (RA): evidence of RANTES and macrophage inflammatory protein (MIP)-1 beta production by synovial T cells | Q71708739 | ||
| The chemoattractant activity of rheumatoid synovial fluid for human lymphocytes is due to multiple cytokines | Q71778731 | ||
| Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis | Q71781127 | ||
| Analysis of serial synovial biopsies in patients with rheumatoid arthritis: description of a control group without clinical improvement after treatment with interleukin 10 or placebo | Q73101125 | ||
| The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis | Q73395900 | ||
| Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent | Q74165253 | ||
| Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirt | Q74175879 | ||
| Expression of chemokines and matrix metalloproteinases in early rheumatoid arthritis | Q74523509 | ||
| Rheumatoid arthritis | Q74541001 | ||
| Chemokines regulate IL-6 and IL-8 production by fibroblast-like synoviocytes from patients with rheumatoid arthritis | Q74844694 | ||
| RANTES expression and contribution to monocyte chemotaxis in arthritis | Q77359406 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 715-721 | |
| P577 | publication date | 2003-08-01 | |
| P1433 | published in | Annals of the Rheumatic Diseases | Q4767876 |
| P1476 | title | Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis | |
| P478 | volume | 62 |
| Q95359391 | Q95359391 |
| Q64232055 | -How Does It Alleviate Chronic Pain? |
| Q46197457 | 11th annual Inflammatory and Immune Diseases Drug Discovery and Development Summit 12-13 March 2007, San Francisco, USA. |
| Q37707714 | Activation of the cholinergic anti-inflammatory system by nicotine attenuates arthritis via suppression of macrophage migration |
| Q37683772 | Anti-chemokine small molecule drugs: a promising future? |
| Q50779652 | CC and CXC chemokine receptors mediate migration, proliferation, and matrix metalloproteinase production by fibroblast-like synoviocytes from rheumatoid arthritis patients. |
| Q45962394 | CCL2/CCR2, but not CCL5/CCR5, mediates monocyte recruitment, inflammation and cartilage destruction in osteoarthritis. |
| Q37879210 | CCR1 as a target for multiple myeloma |
| Q35234755 | CCR1 plays a critical role in modulating pain through hematopoietic and non-hematopoietic cells |
| Q38176229 | CCR6 and CCL20: emerging players in the pathogenesis of rheumatoid arthritis. |
| Q38599089 | CXCR3 plays a critical role for host protection against Salmonellosis |
| Q36465497 | Cells of the synovium in rheumatoid arthritis. Macrophages |
| Q26824580 | Cellular targeting in autoimmunity |
| Q35636896 | Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis |
| Q24800857 | Chemokine blockade: a new era in the treatment of rheumatoid arthritis? |
| Q37349685 | Chemokine receptor antagonists: overcoming developmental hurdles |
| Q24803643 | Chemokine receptors in the rheumatoid synovium: upregulation of CXCR5 |
| Q34051768 | Chemokines and chemokine receptors in arthritis |
| Q37849900 | Chemokines as targets for therapy |
| Q35553416 | Chemokines in joint disease: the key to inflammation? |
| Q91199065 | Chemokines in rheumatic diseases: pathogenic role and therapeutic implications |
| Q36262470 | Chemokines: their role in rheumatoid arthritis |
| Q40365547 | Cloning, expression, and functional characterization of cynomolgus monkey (Macaca fascicularis) CC chemokine receptor 1. |
| Q42186834 | EP2/EP4 signalling inhibits monocyte chemoattractant protein-1 production induced by interleukin 1beta in synovial fibroblasts. |
| Q48268499 | Efficacy, safety and tolerability of the CCR1 antagonist BAY 86-5047 for the treatment of endometriosis-associated pelvic pain: a randomized controlled trial. |
| Q38188862 | Emerging immunotherapies for rheumatoid arthritis. |
| Q38110963 | Emerging therapies for rheumatoid arthritis |
| Q30488975 | Evaluation of arthroscopy and macroscopic scoring |
| Q34896763 | Expression of the inflammatory chemokines CCL5, CCL3 and CXCL10 in juvenile idiopathic arthritis, and demonstration of CCL5 production by an atypical subset of CD8+ T cells |
| Q43492890 | Health-related quality of life in young adult patients with rheumatoid arthritis in Iran: reliability and validity of the Persian translation of the PedsQL™ 4.0 Generic Core Scales Young Adult Version. |
| Q37070343 | Identifying targets for COPD treatment through gene expression analyses. |
| Q36401905 | Immunohistological assessment of the synovial tissue in small joints in rheumatoid arthritis: validation of a minimally invasive ultrasound-guided synovial biopsy procedure. |
| Q39442065 | Increased BMP expression in arthrofibrosis after TKA. |
| Q91907748 | Influence of the regulatory peptide galanin on cytokine expression in human monocytes |
| Q41809691 | Inhibition of TNF alpha during maturation of dendritic cells results in the development of semi-mature cells: a potential mechanism for the beneficial effects of TNF alpha blockade in rheumatoid arthritis |
| Q41961746 | Inhibition of inflammation but not ankylosis by glucocorticoids in mice: further evidence for the entheseal stress hypothesis |
| Q35994130 | Is there a role of synovial biopsy in drug development? |
| Q41849684 | Macrophages and angiogenesis in rheumatic diseases |
| Q36327429 | Molecular mechanisms of cell recruitment to inflammatory sites: general and tissue-specific pathways |
| Q33516229 | Monocyte scintigraphy in rheumatoid arthritis: the dynamics of monocyte migration in immune-mediated inflammatory disease |
| Q34153125 | Monocytes/macrophages express chemokine receptor CCR9 in rheumatoid arthritis and CCL25 stimulates their differentiation |
| Q37790697 | N-aryl pyrazoles, indazoles and azaindazoles as antagonists of CC chemokine receptor 1: patent cooperation treaty applications WO2010/036632, WO2009/134666 and WO2009/137338 |
| Q33258042 | Novel insights in the regulation of CCL18 secretion by monocytes and dendritic cells via cytokines, toll-like receptors and rheumatoid synovial fluid |
| Q36623081 | Novel therapies for rheumatoid arthritis |
| Q46441158 | Overcoming hurdles in developing successful drugs targeting chemokine receptors |
| Q45999111 | Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose. |
| Q41603563 | Pharmacological blockade of CCR1 ameliorates murine arthritis and alters cytokine networks in vivo |
| Q51465120 | Phase I evaluation of the safety, pharmacokinetics and pharmacodynamics of CP-481,715. |
| Q42242681 | Protective effects of Pogostemon cablin Bentham water extract on inflammatory cytokine expression in TNBS-induced colitis in rats |
| Q38102876 | Regulation of TNF-α with a focus on rheumatoid arthritis |
| Q24817151 | Reliability of computerized image analysis for the evaluation of serial synovial biopsies in randomized controlled trials in rheumatoid arthritis |
| Q90642824 | Role of Chemokines and Chemokine Receptors in Rheumatoid Arthritis |
| Q37833076 | Role of endothelial chemokines and their receptors during inflammation |
| Q40467514 | Site-directed mutagenesis of CC chemokine receptor 1 reveals the mechanism of action of UCB 35625, a small molecule chemokine receptor antagonist. |
| Q36173601 | Standardisation of synovial tissue infiltrate analysis: how far have we come? How much further do we need to go? |
| Q38647749 | Successes and failures of chemokine-pathway targeting in rheumatoid arthritis |
| Q35637474 | Synovial inflammation does not change in the absence of effective treatment: implications for the use of synovial histopathology as biomarker in early phase clinical trials in rheumatoid arthritis |
| Q39701973 | Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis |
| Q39431367 | Synovial tissue research: a state-of-the-art review |
| Q37978861 | Synovial tissue response to treatment in rheumatoid arthritis |
| Q26797338 | T Cell Migration in Rheumatoid Arthritis |
| Q36150612 | Targeting cellular adhesion molecules, chemokines and chemokine receptors in rheumatoid arthritis |
| Q39158831 | The Multifunctional Role of the Chemokine System in Arthritogenic Processes |
| Q47390076 | The Role of Macrophages in the Response to TNF Inhibition in Experimental Arthritis |
| Q53519868 | The chemokine receptor CCR5 genetic polymorphism and expression in rheumatoid arthritis patients. |
| Q41822795 | The needle and the damage done |
| Q36992526 | The role of chemokines in leucocyte-stromal interactions in rheumatoid arthritis |
| Q36360715 | The role of chemokines in rheumatoid arthritis and osteoarthritis |
| Q37948866 | Therapeutic potential of CCR1 antagonists for multiple myeloma. |
| Q37672124 | Transcription factor NFAT5 promotes macrophage survival in rheumatoid arthritis |
| Q43239473 | Tumor necrosis factor α- and interleukin-1β-dependent induction of CCL3 expression by nucleus pulposus cells promotes macrophage migration through CCR1. |
| Q36993260 | Vascular involvement in rheumatic diseases: 'vascular rheumatology'. |
| Q28742993 | Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritis |
| Q38068590 | Why is biologic therapy useful in spondyloarthritis? Knowledge from synovial immunopathologic studies of spondyloarthritis |
Search more.